H.C. Wainwright lowered the firm’s price target on Cognition Therapeutics (CGTX) to $5 from $6 and keeps a Buy rating on the shares. The firm expects a “somewhat lengthened path” to market for zervimesine.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX: